All In Biotech

Drug Trial Radar · NCT07220785

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients With Generalized Lipodystrophy (LAGO)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

May 19, 2028

Study completion Sep 8, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the body at different times. This is a 2-part study: Part A is an efficacy study in pediatric and adult participants, Part B is a safety and pharmacokinetic study in pediatric participants. The study is researching several other questions, including: * How mibavademab affects the amount of sugar in the blood * How mibavademab affects the amount of fat (triglycerides) in the blood * How mibavademab affects the amount of fat that has built up in the liver * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Generalized Lipodystrophy

Interventions

  • MibavademabDrug

    Administered as per the protocol

  • PlaceboDrug

    Administered as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin A1c (HbA1c)Time frame: Through 36 weeks of exposure to mibavademab
  2. Percent change in fasting Triglycerides (TG)Time frame: Through 36 weeks of exposure to mibavademab
  3. Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 15 months
  4. Severity of TEAEsTime frame: Up to 15 months
  5. Concentrations of total mibavademab in serumTime frame: Up to 15 months

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Instituto Estadual de Diabetes e Endcrinologia

    Rio de Janeiro, Brazil · Recruiting

  • Walter Cantidio University Hospital, Federal University of Ceara - Ebserh

    Fortaleza, Ceará, Brazil · Recruiting

  • Centro de Pesquisas Clinicas de Natal (Cepclin)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • UPCO - HCPA - Universidade Federal do Rio Grande do Sul - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Das Clinicas - School of Medicine Ribeirao Preto, University of Sao Paulo

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Hopital Universitaire Robert-Debre

    Paris, France · Recruiting

  • Assistance Publique-Hopitaux de Paris (AP-HP)

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.